CoChat

Quadruple adenine base-edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease-engineered T cells

Engel, Nils W., Steinfeld, Israel, Ryan, Daniel, Anupindi, Kusala, Kim, Samuel, Wellhausen, Nils, Chen, Linhui, Wilkins, Katherine, Baker, Daniel J., Rommel, Philipp C., Jarocha, Danuta, Gohil, Mercy, Zhang, Qian, Milone, Michael C., Fraietta, Joseph A., Davis, Megan, Young, Regina M., June, Carl H. · 2025 · Proceedings of the National Academy of Sciences
Cited by 39

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Genome-editing technologies have enabled the clinical development of allogeneic cellular therapies, yet the optimal gene-editing modality for multiplex editing of therapeutic T cell product manufacturing remains elusive. In this study, we conducted a comprehensive comparison of CRISPR/Cas9 nuclease and adenine base editor (ABE) technologies in generating allogeneic chimeric antigen receptor (CAR) T cells, utilizing extensive in vitro and in vivo analyses. Both methods achieved high editing efficiencies across four target genes, critical for mitigating graft-versus-host disease and allograft rejection: TRAC or CD3E , B2M , CIITA , and PVR . Notably, ABE demonstrated higher manufacturing yields and distinct off-target profiles compared to Cas9, with translocations observed exclusively in Cas9-edited products. Functionally, ABE-edited CAR T cells exhibited superior in vitro effector functions under continuous antigen stimulation, including enhanced proliferative capacity and increased surface CAR expression. Transcriptomic analysis revealed that ABE editing resulted in reduced activation of p53 and DNA damage response pathways at baseline, along with sustained activation of metabolic pathways during antigen stress. Consistently, Assay for Transposase-Accessible Chromatin using sequencing data indicated that Cas9-edited, but not ABE-edited, CAR T cells showed enrichment of chromatin accessibility peaks associated with double-strand break repair and DNA damage response pathways. In a preclinical leukemia model, ABE-edited CAR T cells demonstrated improved tumor control and extended overall survival compared to their Cas9-edited counterparts. Collectively, these findings position ABE as superior to Cas9 nucleases for multiplex gene editing of therapeutic T cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.2427216122

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Research works printed but not linked: 55

  1. 10.1056/NEJMra1706169 · DOI · Paper page
  2. 10.1038/s41571-023-00754-1 · DOI · Paper page
  3. 10.1200/JCO.2024.42.16_suppl.6504 · doi:10.1200/jco.2024.42.16_suppl.6504
  4. U. Uslu, C. H. June, Beyond the blood: Expanding CAR T cell therapy to solid tumors. Nat. Biotechnol., 10.1038/s41587-024-02446-2 (2024). · DOI · Paper page
  5. 10.1038/s41586-023-06243-w · DOI · Paper page
  6. 10.1016/j.cell.2024.07.056 · DOI
  7. 10.1182/blood.2022016204 · DOI
  8. 10.1038/s41573-019-0051-2 · DOI · Paper page
  9. 10.1016/j.cell.2024.01.035 · DOI
  10. 10.1038/s41579-022-00739-4 · DOI · Paper page
  11. 10.1016/j.omtm.2021.10.008 · DOI
  12. 10.1182/blood.2022015825 · DOI
  13. 10.1016/j.cell.2023.08.041 · DOI · Paper page
  14. 10.1038/nature17946 · DOI · Paper page
  15. 10.1016/S1074-7613(00)80681-0 · DOI · Paper page
  16. 10.1158/2326-6066.CIR-18-0508 · DOI · Paper page
  17. 10.1093/intimm/3.4.359 · DOI
  18. S. Agarwal, N. Wellhausen, B. L. Levine, C. H. June, Production of human CRISPR-engineered CAR-T cells. J. Vis. Exp. 169, (2021), 10.3791/62299. · DOI
  19. 10.1038/s41586-021-03609-w · DOI · Paper page
  20. 10.1126/science.1225829 · DOI · Paper page
  21. 10.1126/scitranslmed.adi1145 · DOI
  22. 10.1158/2326-6066.CIR-24-0251 · DOI
  23. 10.1056/NEJMoa1215134 · DOI · Paper page
  24. 10.1016/j.jsbmb.2009.02.008 · DOI
  25. 10.1016/j.stem.2024.06.011 · DOI
  26. 10.1016/j.ymthe.2019.01.014 · DOI · Paper page
  27. 10.1186/s13059-024-03434-0 · DOI
  28. 10.1038/s41551-024-01277-5 · DOI
  29. 10.1016/j.immuni.2023.09.001 · DOI · Paper page
  30. 10.1182/blood.2020005185 · DOI · Paper page
  31. 10.1016/S1074-7613(00)00066-2 · DOI · Paper page
  32. 10.1016/0008-8749(88)90073-1 · doi:10.1016/0008-8749(88)90073-1
  33. 10.1182/blood-2010-08-300954 · DOI
  34. 10.1186/s13059-015-0784-0 · DOI · Paper page
  35. 10.4049/jimmunol.1602086 · DOI · Paper page
  36. 10.1016/j.cell.2021.11.016 · DOI · Paper page
  37. 10.1002/advs.202309004 · DOI
  38. 10.3389/fimmu.2017.01956 · DOI
  39. 10.1158/2767-9764.CRC-21-0157 · DOI
  40. M.-Y. Lin, H. Yoon, A. Nguyen, B. Sasu, T. Pertel, Allogeneic CAR T cells derived from younger donor T cells have more desirable T cell phenotype and better in vitro functionality (abstract #1252 in 2022 ASGCT Annual Meeting Abstracts). Mol. Ther. 30, S586 (2022).
  41. A. Prodeus , P205 lipid nanoparticles (LNPs) as a superior CRISPR/Cas9 delivery modality for highly efficient multiplex gene editing of T cells for adoptive cell therapy. Hum. Gene Ther. 32, 19–20 (2021).
  42. 10.1182/blood.2022019333 · DOI · Paper page
  43. S. Umetani , 327 Evaluation of ex vivo gene editing efficiency in human primary T cells by mRNA-LNP. J. ImmunoTher. Cancer 12, A380 (2024).
  44. 10.1038/s41551-023-01032-2 · DOI
  45. 10.1038/s41587-023-01756-1 · DOI
  46. 10.3389/fimmu.2022.1007579 · DOI · Paper page
  47. 10.1038/nprot.2009.22 · DOI · Paper page
  48. 10.1126/sciadv.ade2526 · DOI
  49. 10.1089/crispr.2019.0074 · DOI · Paper page
  50. 10.1038/s41587-020-0439-x · DOI · Paper page
  51. 10.1093/bioinformatics/btp616 · DOI · Paper page
  52. 10.1038/nbt.1630 · DOI · Paper page
  53. N.W. Engel Quadruple adenine base edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease engineered T cells [ATAC-seq]. Gene Expression Omnibus. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290620. Deposited 28 February 2025.
  54. N. W. Engel Quadruple adenine base edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease engineered T cells [RNA-seq]. Gene Expression Omnibus. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290621. Deposited 28 February 2025.
  55. N. W. Engel Quadruple adenine base edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease engineered T cells. BioProject NCBI. https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA1235253. Deposited 14 March 2025.

Cited by

See all 39

Metadata

Authors
Engel, N. W., Steinfeld, I., Ryan, D., Anupindi, K., Kim, S., Wellhausen, N., Chen, L., Wilkins, K., Baker, D. J., Rommel, P. C., Jarocha, D., Gohil, M., Zhang, Q., Milone, M. C., Fraietta, J. A., Davis, M., Young, R. M., & June, C. H.
Affiliations
  • Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania
  • Agilent Research Laboratories
  • Institute for Biomedical Informatics, Perelman School of Medicine, University of Pennsylvania
Venue
Proceedings of the National Academy of Sciences
Published
2025-05-05
Volume
122
Issue
20
ISSN
  • 0027-8424
  • 1091-6490
Cited by
39
References
30
Language
en
Funders
  • US NIH, National Cancer Institute (1-U54 CA244711)
  • Agilent Foundation (Thought Leader Award 2020)
  • Gilead | Kite Pharma (Sponsored Research)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Quadruple adenine base-edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease-engineered T cells. https://app.cochat.ai/papers/10.1073/pnas.2427216122
The paper
Engel, N. W., Steinfeld, I., Ryan, D., Anupindi, K., Kim, S., Wellhausen, N., Chen, L., Wilkins, K., Baker, D. J., Rommel, P. C., Jarocha, D., Gohil, M., Zhang, Q., Milone, M. C., Fraietta, J. A., Davis, M., Young, R. M., & June, C. H. (2025). Quadruple adenine base-edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease-engineered T cells. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2427216122

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.